Longer estrogen exposure tracks with less brain small-vessel injury in older women
A study of older women adds another piece to the long-running question of how sex hormones shape brain aging. In this cohort, lifetime estrogen exposure was associated with healthier markers of cerebrovascular integrity, including less evidence of cerebral small vessel disease and better-preserved white matter. The signal was strongest for later menopause and for women who had used menopausal hormone therapy.
The biology is plausible. Estrogen has vascular effects that extend beyond reproduction, including influences on endothelial function, cerebral blood flow, and the integrity of the small vessels that nourish deep brain tissue. When those vessels are injured over time, white matter changes accumulate, lacunes can appear, and the brain may become more vulnerable to cognitive decline. In that context, the study’s findings point toward a mechanism worth watching rather than a clinical prescription to change practice immediately.
A cohort of 352 women with brain imaging and reproductive history
Investigators drew participants from the Gothenburg H70-1944 Birth Cohort, a longitudinal Swedish study. The analysis included 352 women with an average age of 70, all of whom had brain MRI scans and no neurological conditions such as dementia. A subset of 205 women also returned for MRI follow-up five years later.
Each participant reported reproductive history and hormone exposure, including age at first menstruation, age at menopause, oral contraceptive use, and menopausal hormone therapy. The average reproductive span was just over 37 years. Researchers then assessed imaging markers tied to brain vascular health and neurodegeneration, including indicators of white matter integrity and features of cerebral small vessel disease.
The pattern was straightforward in one respect: a longer reproductive lifespan was associated with lower small-vessel disease burden. Age at menopause carried the association, while age at menarche did not show a meaningful link. In practical terms, later menopause appeared to correspond to less vascular injury in the brain at age 70.
A single sentence captures the core result: later menopause tracked with less brain vascular damage.
Menopausal hormone therapy linked to better white matter preservation
Hormone exposure outside the reproductive years also mattered. Women who had used oral contraceptives or menopausal hormone therapy showed greater white matter integrity, although the oral contraceptive association did not hold after correction. By contrast, menopausal hormone therapy remained linked to lower cerebral small vessel disease burden.
White matter is the brain’s wiring system. It connects regions that must communicate efficiently for memory, attention, and executive function, and it is especially sensitive to vascular injury. Better preservation of that tissue suggests a lower cumulative burden of microvascular damage. In the same cohort, later menopause was also linked to lower odds of one small-vessel marker, lacunes, which are small areas of tissue loss caused by disrupted blood supply.
The combined exposure analysis was more striking. Women who had used both oral contraceptives and menopausal hormone therapy had lower odds of cerebral small vessel disease and better global white matter integrity than women who had used neither. The study does not prove additive protection, but it does suggest that duration and timing of estrogen exposure may shape the aging brain in ways that are visible on MRI.
APOE-ε4 carriers showed a separate signal in Alzheimer’s-vulnerable regions
The analysis also examined APOE-ε4, the genetic variant known to raise Alzheimer’s disease risk. Among carriers, menopausal hormone therapy was associated with greater thickness in brain regions vulnerable to Alzheimer’s disease. Those findings did not persist after correction, so they cannot be treated as definitive. Even so, the direction of effect aligns with the broader idea that estrogen may be relevant not only to vascular aging but also to the structural resilience of regions involved in dementia.
At the five-year follow-up, menopausal hormone therapy trended toward a slower increase in white matter hyperintensity volume, another marker of cerebral small vessel disease. The signal was not strong enough to settle the question, but it fits the same biological frame: less vascular injury over time may slow the structural changes that often precede cognitive decline.
Observational data cannot justify hormone therapy for brain protection
The limitations are substantial and clinically important. This was an observational study, so it cannot establish cause and effect. The investigators lacked detailed data on how long women used menopausal hormone therapy, and self-reported reproductive histories may not be perfectly accurate. Information on gender identity and adverse experiences related to hormone use was limited, and the definition of surgical menopause differed from that used in some other research because it focused on removal of both ovaries rather than hysterectomy.
The follow-up cohort was smaller, the observation window was relatively short, and it included only women without cognitive impairment at follow-up. Selection bias may have influenced who returned for imaging. Some analyses also relied on small subsamples, including cerebrospinal fluid work, and only certain findings remained statistically significant after correction.
Those constraints matter because they separate a biologically credible association from a treatment recommendation. The study does not justify using menopausal hormone therapy solely to protect the brain.
Why the findings still matter for dementia prevention research
Women account for roughly two-thirds of the dementia population, and Alzheimer’s disease risk is higher in women than in men. Midlife and late-life hormone exposure may be one of several factors shaping that disparity. Estrogen’s vascular effects offer a reasonable route for future investigation: if the hormone helps preserve small vessels and white matter, it may influence the cascade that leads from silent vascular injury to later cognitive decline.
Dung Trinh, MD, who was not involved in the study, said continued work in this area is important because menopause represents a major biological transition that may affect brain metabolism and long-term neurologic health. He also emphasized that even modest risk reduction, if confirmed across a large population, could have public-health value.
The authors were explicit about the current clinical boundary. The findings are not intended to change recommendations for oral contraceptives or menopausal hormone therapy. There is insufficient evidence to prescribe menopausal hormone therapy solely for long-term brain protection, and treatment decisions still need to account for symptoms, age, time since menopause, medical history, and individual risk factors.
For now, the study sharpens the question rather than answers it: how much of aging women’s brain health is shaped by the duration and timing of estrogen exposure, and which vascular changes can be modified before memory loss begins?